NOTICE OF LIMITED COMPETITION DISSEMINATING EVIDENCE-BASED INTERVENTION RESEARCH PRODUCTS Release Date: December 31, 2001 NOTICE: NOT-CA-02-007 National Cancer Institute (http://cancer.gov/) The National Cancer Institute"s (NCI) Division of Cancer Control and Population Sciences (DCCPS) announces a limited competition for competing supplemental applications to NCI-funded research projects supported by R01, P01, P50, U01 and U19 grant mechanisms. Most researchers who propose to develop and test cancer control interventions either explicitly or implicitly intend to disseminate the interventions within the populations from which the sample is drawn if the interventions prove efficacious. However, without financial support for the costs of dissemination, active dissemination rarely occurs. The purpose of these supplements is to fund the dissemination of promising intervention programs and products. This includes interventions where statistical significance and potential public health/clinical significance suggest the merits of dissemination to the broader population from which the intervention study sample was originally drawn. The supplement also may support cost-effectiveness evaluations of interventions, qualitative and quantitative research needed to adapt intervention products for use after formal research evaluation has ended and dissemination of intervention products. These supplements have been designed to provide one-year funding to cancer control investigators whose intervention efficacy data have been analyzed, who are in the final years of their R01, P01, P50, U01 or U19 awards. Intervention research across the cancer control continuum that may be eligible for these supplements, includes: tobacco use prevention and cessation, promotion of appropriate changes in diet and physical activity, reduction of sun exposure and UV radiation exposure, facilitating informed decisions about genetic testing for cancer susceptibility, enhancing screening for breast, cervix and colorectal cancers, quality of care as well as improving coping skills and quality of life for cancer survivors and their families. Detailed instructions for applying for this supplement can be found at: http://cancercontrol.cancer.gov/funding.html. Requests should contain enough detail to allow assessment of the scientific merit of the proposed dissemination plans and the appropriateness of the request for supplemental funding. Budgets should not exceed $100,000 in direct costs for a time period not exceeding 12 months. If there are extenuating circumstances that require a marginally larger budget, these should be well documented and justified. All requests require an itemized budget and must be countersigned by the grantee institution"s business office. Requests for supplements under this program must comply with NIH policies for inclusion of women, minorities, and children in research involving human subjects. Submissions may be made to this supplement no earlier than 24 months prior to the end of the last year of a currently funded NCI intervention research R01, P01, P50, U01 or U19 and no later than March 28, 2002. There must be an active parent grant during the entire funding period of the supplement. Therefore, if the parent grant ends before 9/30/03, the grantee must apply for no-cost extension. Applicants with Type 2 awards can request a supplement to their Type 2 award in order disseminate interventions tested in their Type 1 awards if, and only if, no resources were awarded in the type 2 grant for the dissemination of type 1 interventions. In this particular case, the supplement (if awarded) will be linked to the Type 2 award to disseminate the evidence-based intervention tested in the original R01, P01, P50, U01 or U19 (Type 1) project. Requests will undergo review for scientific merit by extramural reviewers with expertise in the cancer control intervention area and/or in dissemination and diffusion research. Awards will be determined on the basis of scientific merit, program relevance, dissemination potential, and availability of funds. Special consideration will be given to applications that plan to disseminate interventions tested in low income and ethnically diverse populations. The earliest anticipated award date for this program will be September 2002. Inquiries related to this notice should be addressed to the NCI Program Director for the particular R01, P01, P50, U01 or U19 for which the supplement is being requested. Applicants are STRONGLY ENCOURAGED to discuss the efficacy data (e.g. effect sizes, consistency with prior research, relevance to target populations) supporting their competing supplement request from the original project with their respective NCI research project Program Director prior to submission. INQUIRIES Direct inquiries concerning the programmatic matters to: Jon F. Kerner, Ph.D. Assistant Deputy Director for Research Dissemination and Diffusion Division of Cancer Control and Population Sciences 6130 Executive Boulevard Executive Plaza North, Room 6144 Rockville, MD 20852 Telephone: (301) 594-7294 E-mail: jon.kerner@nih.gov Direct inquiries regarding fiscal matters should be made to: Ms. Crystal Wolfrey Grants Administration Branch 6120 Executive Boulevard Executive Plaza South, Room 243 Rockville, MD 20852 Telephone: (301) 496-8634 E-mail: crystal.wolfrey@nih.gov Direct inquiries regarding review matters to: Referral Officer Division of Extramural Activities National Cancer Institute 6116 Executive Boulevard, Room 8041, MSC 8329 Bethesda, MD 20892-8329 Rockville, MD 20852 (for express/courier service) Telephone: (301) 496-3428 Fax: (301) 402-0275 Email: ncidearefof-r@mail.nih.gov
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
| ||||||
Department of Health and Human Services (HHS) |
||||||
NIH... Turning Discovery Into Health® |